Grant name: Molecular Mechanisms of Combination Adjuvants (MMCA)
Funding organization: National Institutes of Health (NIH)
Total funding amount: $2.56 million
Duration: Maximum project period of five years
Primary objective: To support research studies on combination adjuvants to improve vaccine design.
Funding source: National Institute of Allergy and Infectious Diseases (NIAID)
Funding type: Research Project Grant (R01)
Significance: Addresses the need for improved vaccine efficacy through combination adjuvants.
Grant frequency: One-time funding opportunity.
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) status)
For-Profit Organizations (including Small Businesses)
Local, State, County, City Governments
Indian/Native American Tribal Governments (both Federally Recognized and others)
Federal Government Agencies
Foreign Organizations
Must complete registrations with System for Award Management (SAM), eRA Commons, and Grants.gov.
Principal Investigator(s) must have an eRA Commons account.
Investigate mechanisms of action of combination adjuvants.
Focus on immune mechanisms in animal models and validation in complex model systems.
Define molecular and immunological mechanisms leading to long-term protective immunity against infectious diseases.
Research must include examination of immune mechanisms in animal models.
In vitro systems and human samples are encouraged.
Application budgets expected to be less than $500,000 in direct costs per year.
Minimum direct costs for collaborative projects: $50,000 per year starting in Year 2.
Posted Date: January 13, 2025
Open Date: May 10, 2025
Application Due Date: June 11, 2025
Earliest Start Date: June 10, 2025
Must comply with NIH Grants Policy Statement and other federal regulations.
Applications must be submitted electronically through Grants.gov.
Follow specific instructions in the Research Instructions in the How to Apply - Application Guide.